Research Analysts Set Expectations for OVID FY2026 Earnings

Ovid Therapeutics Inc. (NASDAQ:OVID) – Equities research analysts at HC Wainwright issued their FY2026 earnings per share estimates for Ovid Therapeutics in a research note issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.60) for the year. HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.19 million.

OVID has been the subject of several other reports. BTIG Research decreased their price objective on shares of Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a report on Monday. Wedbush restated an “outperform” rating and set a $3.00 price target (down from $4.00) on shares of Ovid Therapeutics in a report on Wednesday, March 12th. Finally, Oppenheimer raised Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price target on the stock in a research report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $3.03.

Ovid Therapeutics Trading Up 4.5 %

Shares of OVID stock opened at $0.44 on Tuesday. Ovid Therapeutics has a 12 month low of $0.42 and a 12 month high of $3.45. The company has a market cap of $31.58 million, a PE ratio of -0.95 and a beta of 0.29. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.18. The business’s 50 day moving average is $0.60 and its two-hundred day moving average is $0.92.

Institutional Trading of Ovid Therapeutics

A number of hedge funds have recently bought and sold shares of OVID. FMR LLC raised its position in shares of Ovid Therapeutics by 1,907.4% during the third quarter. FMR LLC now owns 50,225 shares of the company’s stock valued at $59,000 after buying an additional 47,723 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Ovid Therapeutics by 4,128.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 220,401 shares of the company’s stock valued at $260,000 after acquiring an additional 215,189 shares in the last quarter. Verition Fund Management LLC acquired a new position in Ovid Therapeutics in the 3rd quarter valued at approximately $88,000. XTX Topco Ltd lifted its position in shares of Ovid Therapeutics by 46.2% in the 3rd quarter. XTX Topco Ltd now owns 38,230 shares of the company’s stock worth $45,000 after acquiring an additional 12,076 shares during the period. Finally, Barclays PLC grew its holdings in shares of Ovid Therapeutics by 311.2% during the 3rd quarter. Barclays PLC now owns 84,175 shares of the company’s stock worth $98,000 after purchasing an additional 63,702 shares in the last quarter. 72.24% of the stock is owned by institutional investors.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.